Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 8/20 | 0.57 |
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102197 | 0.92 | MPL (0.48) | MPLPARP1NPC1RAB9ATP53 | |
| SCHEMBL1102077 | 0.91 | MPL (0.69) | MPLPARP1NPC1RAB9ATP53 | |
| SCHEMBL1102085 | 0.90 | MPL (0.57) | MPLPARP1NPC1RAB9ATP53 | |
| SCHEMBL1102218 | 0.85 | MPL (0.51) | MPLPARP1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL1102116 | 0.83 | MPL (0.68) | MPLPARP1NPC1RAB9ATP53 | |
| SCHEMBL1102282 | 0.82 | MPL (0.49) | MPLNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1102236 | 0.82 | MPL (0.49) | MPLPARP1NPC1RAB9ATP53 | |
| SCHEMBL1102083 | 0.81 | MPL (0.63) | MPLPARP1IDO1TDO2 | |
| SCHEMBL1092179 | 0.81 | MPL (0.85) | MPLPARP1 | |
| SCHEMBL1102210 | 0.78 | MPL (0.46) | MPLPARP1SMN1; SMN2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-1910338-B1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2010-08-25 | — | — | EP | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | MPL 1/4885PARP1 782/4885NPC1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.